INS and COVID-19: It was originally thought that some anti-diabetes treatment (such as metformin, PPARs, DPP4 inhibitors, GLP-1R agonists, SGLT2 inhibitors and insulin therapy) could influence the course of COVID-19; however, no convincing evidence has emerged to support this view.